Australian Rotavirus Surveillance Program: Annual Report, 2019

Sarah Thomas, Celeste M. Donato, Susie Roczo-Farkas, Jenny Hua, Julie E. Bines, Australian Rotavirus Surveillance Group

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Abstract: This report, from the Australian Rotavirus Surveillance Program and collaborating laboratories Australia-wide, describes the rotavirus genotypes identified in children and adults with acute gastroenteritis during the period 1 January to 31 December 2019. During this period, 964 faecal specimens had been referred for rotavirus G- and P- genotype analysis, including 894 samples that were confirmed as rotavirus positive. Of these, 724/894 were wild-type rotavirus strains and 169/894 were identified as vaccine-like. A single sample could not be determined as wild-type or vaccine-like due to poor sequencing. Genotype analysis of the 724 wild-type rotavirus samples from both children and adults demonstrated that G3P[8] was the dominant genotype nationally, identified in 46.7% of samples, followed by G2P[4] in 8.8% of samples. The Australian National Immunisation Program (NIP) changed to the exclusive use of Rotarix as of 1 July 2017. The NIP had previously included two live-attenuated oral vaccines: Rotarix (monovalent, human) and RotaTeq (pentavalent, human-bovine reassortant) in a state-based vaccine selection. Continuous surveillance is imperative to determine the effect of this change in rotavirus vaccine schedule on the genotype distribution and diversity in Australia.

Original languageEnglish
Number of pages25
JournalCommunicable Diseases Intelligence
Volume45
DOIs
Publication statusPublished - 29 Jan 2021
Externally publishedYes

Keywords

  • Australia
  • G3P[8]
  • gastroenteritis
  • genotype
  • Rotarix
  • rotavirus
  • surveillance
  • vaccine

Cite this